Approximately 3% to 4% of patients will discontinue treatment because of gastrointestinal adverse effects
Abstract Diabetes mellitus (DM) and premenstrual syndrome (PMS) are global health challenges
A patch test can help determine whether you can safely use these products
However, as the drug is unlicensed, these trial doses do not constitute an approved dosing regimen for general use
Otras drogas como el Liraglutide, comercializado como Saxenda, y el Tirzepatide bajo los nombres comerciales de Mounjaro, aprobado para tratar diabetes y Zepbound para tratar la obesidad, tambin han demostrado ser efectivas en la reduccin de peso
For patients seeking metabolic support, distinguishing between marketing claims and clinical evidence is crucial